The Molecular Health Guide 3.0 is based on the company’s Dataome technology platform. It compares patient-specific molecular information with biomedical knowledge to provide an interactive, editable, medical report that will help physicians in assessing the range of therapy options based on the genomic profile of the patient.

MH Guide has been registered as an in vitro diagnostic device in the European Union.

Physicians will need to understand and interpret several biomarkers to assess their significance and make a reliable statement on the suitability of a specific cancer therapy.

MH Guide can help in identifying clinically significant variants from whole exome analyses and will offer physician-approved variant interpretations that describe their clinical significance with reference to the patient’s disease.

Physicians can use this knowledge on each variant and follow references to the peer-reviewed sources as a basis for their clinical reports.

Molecular Health claims that the new Version 3.0 has an improved Association for Molecular Pathology (AMP) guideline-compliant biomarker classification scheme and supports Human Genome Variation Society (HGVS) variant nomenclature.

MH Guide 3.0 users can now incorporate results from other important diagnostic tests in their reports, including protein expression, mutational burden, and microsatellite instability.

Customizable gene filters can let physicians to streamline workflow to focus on standard panels for genes of interest.

Along with physician-approved variant interpretations, there are variant details from available from standard sources recommended by variant classification guidelines. These support physicians in assessing clinical significant of a variant.

Molecular Health chief information officer Rudolf Caspary said: “MH Guide 3.0 marks a further milestone in cancer treatment based on the genetic variants in a tumor. It gives the treating oncologist a fast and comprehensive overview of treatment recommendations.

“We can help to significantly facilitate and improve the daily clinical routine of the treating physicians, while delivering well-informed therapy decisions. Ultimately, this benefits patients – and the entire healthcare system.”